Business Wire

Western Union Highlights ESG Progress and Recognitions Received

29.6.2022 15:00:00 EEST | Business Wire | Press release

Share

The Western Union Company (NYSE: WU) today released its 2021 Environmental, Social and Governance (ESG) Report, spotlighting the Company’s ongoing commitment to advancing its strategy and actions aligned with key ESG priorities.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220629005138/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Western Union's 2021 ESG report spotlights the Company’s ongoing commitment to advancing its strategy and actions aligned with key ESG priorities.(Photo: Business Wire)

“People are drawn to work for and do business with companies that make an impact,” said Devin McGranahan, Chief Executive Officer. “This year’s report shows that Western Union continues to make solid progress on our ESG journey, which in turn enables us to effect even more positive change in the communities we serve. I’m proud to work with colleagues who bring their best every day to improve the lives of our customers and communities around the world.”

2021 ESG Highlights

Western Union’s ESG strategy is focused on efforts and areas where the Company can make meaningful impact, including:

  • Furthering economic prosperity: The Company launched a digital banking platform in Germany and Romania, combining money transfer, a multi-currency account and debit card. Western Union believes offering people simple, trusted solutions via digital and retail access points creates pathways for long-term economic success.
  • Promoting the integrity of money movement: Western Union also continued progress on our commitment to money movement that is safe, secure and built on a foundation of integrity. While third-party data show the rate of fraudulent activity across the financial industry is increasing, in 2021 our Company’s reported consumer fraud globally decreased by 10% and we prevented approximately $1.9 billion in fraudulent transactions. These efforts were supported by fraud prevention messages that reached consumers through 121 million consumer fraud touches, a 97% increase over 2020.1
  • Advancing diversity, equity, and inclusion: Another key area of focus for the Company in 2021 was advancing diversity, equity and inclusion (DEI). In 2021, Western Union developed a DEI strategy focused on hiring, development, promotion, retention and cultural change. DEI milestones include:
    • A newly formed DEI program office, naming a Chief Diversity and Talent Officer, a specialized diversity recruiting lead and a full-time DEI program lead; and
    • Achieving gender pay equity globally and racial/ethnicity pay equity in the US.

This year also marks the first time Western Union has disclosed our Company’s Scope 1 and 2 greenhouse gas (GHG) emissions.

Increased Recognition

The Company also reported recognitions for its ESG efforts, including:

  • Recognized as one of the World’s Most Ethical Companies® for the first time;
  • Bloomberg’s Gender Equality Index for the third consecutive year;
  • JUST Capital’s Top 100 Companies Supporting Healthy Families and Communities; and
  • Human Rights Campaign’s Best Place to Work for LGBTQ+ Equality.

For more information and additional details related to our 2021 progress, and to download Western Union’s 2021 Environmental, Social and Governance (ESG) Report, click here.

About Western Union

The Western Union Company (NYSE: WU) is a global leader in cross-border, cross-currency money movement and payments. Western Union’s platform provides seamless cross-border flows and its leading global financial network bridges more than 200 countries and territories and over 130 currencies. We connect consumers, businesses, financial institutions, and governments through one of the world’s widest reaching networks, accessing billions of bank accounts, millions of digital wallets and cards, and a substantial global network of retail locations. Western Union connects the world to bring boundless possibilities within reach. For more information, visit www.westernunion.com.

________________________________

1. Consumer Fraud Awareness Touches are derived from metrics tracked across various platforms, including paid media ads, social media (Facebook, Twitter, YouTube, Community Management), outreach attendees and wu.com/fraudawareness visits. Each platform may have a unique method for quantifying individuals who have consumed anti-fraud content, based on reach, impressions, views, visits and/ or received physical materials. Given that consumers may engage with our content through multiple channels, each “touch” may not be a unique consumer.

WU-G

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Relations:
Claire Treacy
Claire.Treacy@westernunion.com

Investor Relations:
Tom Hadley
WesternUnion.IR@westernunion.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care4.8.2026 10:10:00 EEST | Press release

LabPMM®, an Invivoscribe® subsidiary, today announced the global availability of its new KMT2A measurable residual disease (MRD) testing service. The highly sensitive digital PCR service is available to healthcare providers, clinical researchers, and biopharmaceutical partners through LabPMM’s global laboratory network, with CAP/CLIA-accredited testing available in the U.S. The service addresses a growing need for accurate molecular monitoring in acute leukemias.1,2,3 KMT2A rearrangements (KMT2Ar) are oncogenic drivers in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).4 These rearrangements are present in about 80% of infant cases and 5-15% of childhood and adult leukemia cases.5 KMT2Ar leukemias are associated with chemotherapy resistance, high relapse rates, and poor clinical outcomes.5 The emergence of menin inhibitors is transforming the therapeutic landscape for patients with AML and ALL, particularly those with KMT2A-rearranged and NPM1-mutated disease.6 The

Mosaic Therapeutics appoints Dr Allison Jeynes as Chair of the Board4.8.2026 10:00:00 EEST | Press release

Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds Dr Edward Hodgkin, who remains a Non-Executive Director of the Board. Allison is a UK-trained oncologist and highly-experienced life sciences leader, and brings over three decades of drug development and executive experience to Mosaic Therapeutics. As CEO of Avillion, a clinical development company, for the last 13 years, she has led global teams to achieve a 100% success rate from Phase 3 development through to FDA approval for multiple programs spanning oncology, immunology and respiratory medicine. In addition, she raised funds of around $400M as founder and CEO. Across her career she has contributed to 20 drug approvals, engaging

TOHKnet and Adtran conduct Japan’s first 50G PON trial on a live network4.8.2026 10:00:00 EEST | Press release

Adtran today announced that TOHKnet has completed Japan’s first live network trial demonstrating the coexistence of 50G PON, XGS-PON and EPON on a single fiber. Conducted in Sendai using Adtran’s SDX 6400 Series OLT, the demo showed how the platform enables three generations of PON technology to operate together in a live service environment. The results highlight a realistic path for operators to introduce 50G PON capacity while maintaining continuity for existing services, maximizing the value of deployed fiber assets and reducing the complexity and disruption typically associated with network upgrades. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260803353435/en/ Adtran’s SDX 6400 Series is helping TOHKnet demonstrate how Japan’s operators can migrate to 50G PON without disrupting existing PON services. “As demand for digital services continues to grow, this trial is a key milestone for the future of fiber access in Jap

“HATSUNE MIKU LIGHTS TOKYO” Debuts on July 254.8.2026 10:00:00 EEST | Press release

The Tokyo Metropolitan Government has been presenting year-round projection mapping displays on the Tokyo Metropolitan Government Building, using light and sound to showcase a wide range of artistic expressions as part of its efforts to create new nighttime tourism attractions in Tokyo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260802298570/en/ © Crypton Future Media, INC. On Saturday, July 25, "HATSUNE MIKU LIGHTS TOKYO", featuring the globally beloved virtual singer Hatsune Miku, held its first screening. The work brings the world of the popular song “M@GICAL☆CURE! LOVE ♥ SHOT!” to life across the entire façade of the Tokyo Metropolitan Government Building. Since its launch in February 2024, “TOKYO Night & Light” has welcomed visitors from Japan and around the world, with total attendance surpassing 1.55 million. As one of Tokyo’s emerging landmark attractions, the project continues to captivate audiences through its

Evexta Bio Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate Rupitasertib in Combination with a Selective Estrogen Receptor Degrader in Advanced / Metastatic Breast Cancer4.8.2026 10:00:00 EEST | Press release

Evexta Bio S.A., a precision oncology company, founded by Truffle Capital (founder of Abivax and Carvolix), and focused on the discovery and development of targeted therapies, today announced a clinical collaboration and supply agreement with plans to initiate a Phase 1b study combining its lead investigational compound, rupitasertib, with Roche’s investigational compound giredestrant, a selective estrogen receptor degrader (SERD), for the treatment of ER+, HER2-, ESR1-mutated advanced / metastatic breast cancer. Rupitasertib, is a first-in-class oral dual-node PI3K/AKT/mTOR (PAM) pathway inhibitor, which selectively inhibits S6K and AKT1/3. Rupitasertib was purposefully and rationally designed to target S6K for potent PAM inhibition and AKT1/3 to block the AKT compensatory feedback loop, while sparing AKT2 to avoid hyperglycemia, which we believe will lead to a superior efficacy and safety profile compared to other PAM pathway inhibitors. Under the terms of the agreement, Roche will s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye